|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Kuur_Therapeutics
|
|
gptkbp:business_model
|
biotech innovation
clinical development
partnerships with pharma companies
|
|
gptkbp:ceo
|
gptkb:Dr._Johnson_Lau
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:Canada
gptkb:United_States
ongoing
Phase 1
Phase 2
Phase 3
promising
|
|
gptkbp:collaboration
|
gptkb:Roswell_Park_Comprehensive_Cancer_Center
gptkb:University_of_Buffalo
|
|
gptkbp:collaborations
|
gptkb:Eli_Lilly
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Amgen
|
|
gptkbp:focus
|
gptkb:cancer_treatment
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:founder
|
gptkb:R._Scott_Greer
|
|
gptkbp:headquarters
|
gptkb:Buffalo,_New_York
|
|
gptkbp:healthcare
|
pending
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Athenex
|
|
gptkbp:instruction_set
|
multiple drug candidates
|
|
gptkbp:investment
|
millions of dollars
Venture capital firms
|
|
gptkbp:ipo
|
gptkb:2017
|
|
gptkbp:market_cap
|
approximately $200 million
|
|
gptkbp:partnership
|
gptkb:Celgene_Corporation
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Roche
gptkb:Novartis
|
|
gptkbp:product
|
gptkb:Athenex's_T-cell_therapy
gptkb:Athenex's_intravenous_paclitaxel
gptkb:Athenex's_oral_paclitaxel
gptkb:KX2-391
TCR-T cell therapy
|
|
gptkbp:research_areas
|
gptkb:immunotherapy
combination therapy
oncology
targeted therapy
|
|
gptkbp:research_focus
|
oral drug delivery
chemotherapy formulations
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
ATNX
|
|
gptkbp:subsidiary
|
gptkb:Athenex_Oncology
gptkb:Athenex_Pharma_Solutions
|
|
gptkbp:website
|
www.athenex.com
|
|
gptkbp:bfsParent
|
gptkb:Bayer_AG
gptkb:Bayer
|
|
gptkbp:bfsLayer
|
5
|